![Emiliano Spagnolo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Emiliano Spagnolo has a current job as the Chief Executive Officer at CellPly srl.
Emiliano Spagnolo active positions
Companies | Position | Start |
---|---|---|
CellPly SRL
![]() CellPly SRL Medical SpecialtiesHealth Technology CellPly SRL develops and markets customized diagnostic tools for cancer treatment. The firm specializes in the design and marketing of solutions for defining the efficacy of immunotherapies and chemotherapies on cancer and immune cells. It offers a platform that analyzes ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to readily provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells located close to tumor cells. The firm focuses on helping oncologists selecting the best treatment options, scientists studying cell response to therapy, and pharmaceutical companies increasing drug efficacy and rescuing drugs with limited efficacy through patient stratification. The company was founded by Massimo Bocchi and Roberto Guerrieri in 2013 and is headquartered in Bologna, Italy. | Chief Executive Officer | 2023-07-13 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
CellPly SRL
![]() CellPly SRL Medical SpecialtiesHealth Technology CellPly SRL develops and markets customized diagnostic tools for cancer treatment. The firm specializes in the design and marketing of solutions for defining the efficacy of immunotherapies and chemotherapies on cancer and immune cells. It offers a platform that analyzes ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to readily provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells located close to tumor cells. The firm focuses on helping oncologists selecting the best treatment options, scientists studying cell response to therapy, and pharmaceutical companies increasing drug efficacy and rescuing drugs with limited efficacy through patient stratification. The company was founded by Massimo Bocchi and Roberto Guerrieri in 2013 and is headquartered in Bologna, Italy. | Health Technology |
- Stock Market
- Insiders
- Emiliano Spagnolo